2023年、2024年及2025年上半年，艾米森生命分别实现营业收入623.3万元、723.8万元、651.3万元；分 别实现净利润-6792.2万元、-3863万元和-1390.6万元。公司收入基本来自销售已获国家药监局批准的产 品，即艾长康、艾长健、艾思宁及艾馨甘。 2023年、2024年及2025年上半年，公司研发开支分别为0.23亿元、0.15亿元及0.045亿元。 招股书显示，募集资金将用于：公司核心产品艾馨甘及艾光乐的研发、注册备案及商业化；公司多款管 线产品的研发、注册备案及商业化；提高一般研发能力及提升技术；加强生产设施的自动化；通过潜在 收购或授权引进癌症检测领域的候选产品，持续扩大及多元化公司的产品组合；公司的营运资本及其他 一般企业用途。 将继续依赖有限数量客户 9月28日，武汉艾米森生命科技股份有限公司(简称"艾米森生命")向港交所递交上市申请。 艾米森生命于2015年1月成立，是一家早期癌症检测公司。2023年、2024年及2025年上半年，公司分别 实现净利润-6792.2万元、-3863万元和-1390.6万元。 深耕肿瘤分子检测市场 根据招股书，艾米森生命深耕肿瘤分子检测市场。 ...

点评：作为公司核心高管，金恩林的职务变动可能引发市场对管理层稳定性的短期担忧。不过，京东健 康迅速任命曹冬为新的执行董事和首席执行官，显示出公司应对管理层变动的高效性，有助于稳定市场 信心。 NO.3"早筛第一股"诺辉健康面临摘牌风险 近日，曾被誉为"癌症早筛第一股"的诺辉健康，已经在港交所连续停牌18个月了。按照交易所规定，公 司可能因此被强制退市。2023年8月，一份做空报告称诺辉健康通过不断压货方式，营造九成虚假销售 收入，次年3月，公司审计机构德勤拒绝为其财报背书并提出质疑，导致股票被强制停牌。 丨 2025年9月30日星期二丨 NO.1中国首个获批治疗PFIC的非手术靶向药物上市 近日，益普生宣布其罕见病创新药"蓓尔唯"(通用名：奥德昔巴特胶囊)在中国正式商业上市。去年12 月，该药物在国内获批用于治疗≥6月龄的PFIC患者的瘙痒，是目前中国首个且唯一获批治疗PFIC领域 的非手术靶向药物，目前已被纳入3个省市惠民保国内特药目录及11个省市惠民保海外特药目录。 点评：PFIC是一种罕见的遗传性疾病，发病率为(1~2)/10万，多在新生儿期或1岁以内发病。作为PFIC 的一线治疗药物，奥德昔巴特是目前 ...

Group 1 - The first non-surgical targeted drug for treating PFIC, "Bai Er Wei" (generic name: Odevixibat capsules), has been officially launched in China, marking a significant breakthrough in the accessibility of treatment options for PFIC patients [1] - PFIC is a rare genetic disease with an incidence rate of (1-2)/100,000, typically manifesting in newborns or infants under one year old [1] - Odevixibat is the first and only approved non-surgical targeted drug for PFIC in China, which has been included in the domestic and overseas special drug directories of several provinces [1] Group 2 - JD Health's CEO, Jin Enlin, has resigned for family reasons, effective September 29, with a swift appointment of Cao Dong as the new CEO, indicating the company's efficient management response [2] - The resignation of key executives may raise short-term concerns regarding management stability, but the prompt succession plan aims to maintain market confidence [2] Group 3 - Nohui Health, known as the "first stock in cancer early screening," faces delisting risks after being suspended from trading for 18 months due to a short-selling report alleging inflated sales revenue [3] - The company's auditor, Deloitte, refused to endorse its financial statements, leading to the trading suspension, which could severely impact its future business expansion and fundraising efforts [3] Group 4 - Aimeike's subsidiary has received approval for two minoxidil topical solutions (2% and 5%) from the National Medical Products Administration, expanding its product offerings in the hair loss treatment sector [4] - The introduction of these products is expected to create new revenue growth opportunities for Aimeike and enhance its competitive position in the market [4] - This development reflects Aimeike's strength in research and product innovation, which may boost investor confidence and drive stock price appreciation [4]

每经记者｜林姿辰 每经编辑｜段炼 魏文艺 9月27日，曾被誉为"癌症早筛第一股"的诺辉健康，已经在港交所连续停牌18个月。按照港交所规定，公司可能因此被强制退市。 | 2024.4.8 | 诺辉健康在2024美国癌症研究学会发布结直肠癌早筛液体活检新技术 | | --- | --- | | 2024.1.22 | 诺辉健康发布2023年报盈喜预告:全年总收入超20亿,首年实现税后盈利 | | 2024.1.12 | 诺辉健康朱叶青：公司2023年营收较2020年实现25倍增长! | 官网资料显示，2015年诺辉健康成立于浙江杭州，是中国首家专注于高发癌症居家早筛的生物高科技公司，2021年领先行业首个实现香港联交所成功上 市，成为"中国癌症早筛第一股"，股票代码6606.HK。 诺辉健康针对中国目前高发癌症前3位中的结直肠癌和胃癌，公司已经分别上市并商业化三款明星产品：常卫清®、噗噗管®和幽幽管®。常卫清®是中国 目前唯一获得国家药监局批准的肠癌筛查产品，完成了中国目前唯一癌症筛查大规模前瞻性多中心注册临床试验，适用于40-74岁的结直肠癌高风险人 群。幽幽管®是中国目前唯一获得国家药监局批准的幽门螺杆菌消费 ...

Core Viewpoint - Mirxes-B (02629) has seen a significant stock price increase, rising over 150% from its IPO price of 23.3 HKD, reaching a high of 59.5 HKD, and currently trading at 54.75 HKD with a trading volume of 566 million HKD [1] Company Overview - Mirxes is a Singapore-based company specializing in microRNA (miRNA) technology, focusing on making disease screening and diagnostic solutions accessible in key Asian markets [1] - The company has one core product, GASTROClearTM, along with two other commercialized products, LUNGClearTM and FortitudeTM, and six candidates in preclinical stages [1] Product Details - GASTROClearTM is a blood-based miRNA detection kit consisting of 12 miRNA biomarkers for gastric cancer screening, which received Class C in vitro diagnostic (IVD) certification from the Health Sciences Authority (HSA) of Singapore in May 2019 and has been successfully commercialized in Singapore [1] Market Inclusion - Mirxes has been included in the Hang Seng Composite Index, effective from September 8, which has contributed to its stock price surge and its designation as a stock eligible for the Shanghai-Hong Kong Stock Connect [1]

新加坡癌症早筛龙头企业Mirxes Holding Limited（股票代号：02629.HK，下称"Mirxes觅瑞"），自2025 年5月23日在港交所主板上市后，仅用不足四个月便先后纳入恒生综合指数与港股通标的，其价值获国 际市场高度认可，也为内地投资者开辟了参与生物科技独角兽成长的新路径。 "公司上市不足四个月便纳入恒生综合指数，我们深感荣幸。"Mirxes觅瑞联合创始人兼首席执行官周砺 寒博士表示，"这印证了我们选择在港交所上市的战略正确性，也进一步彰显了公司扩大全球投资者范 围的坚定承诺。" 【关于Mirxes觅瑞】 2025年9月5日香港交易所收市后，恒生指数公司季度检讨结果正式生效，Mirxes觅瑞成功跻身沪港通下 港股通标的名单。自9月8日（星期一）起，这家新加坡生物科技企业正式向内地投资者开放，标志着其 投资者群体将进一步扩容。作为连接内地与香港股市的核心机制，港股通的纳入门槛围绕市值、流动 性、上市表现等关键指标展开，而恒生指数公司每半年一次的系统性指数检讨，正是为了确保标的组合 的代表性与平衡性。Mirxes觅瑞此次"双纳入"，本质是市场对其综合实力的深度肯定。 Mirxes觅瑞（股票 ...

Core Insights - Mirxes Holding Company Limited (Mirxes) has demonstrated significant achievements in its core product commercialization, financial optimization, and R&D pipeline advancement as of June 30, 2025 [1] Financial Performance - Mirxes reported a revenue of $10.5 million for the first half of 2025, marking a 9.4% increase compared to the same period in 2024, driven by a 50% growth in the early detection and precision multi-omics segment [2] - The gross profit reached $7.1 million, a 102.9% increase year-on-year, with the gross margin improving from 49.0% to 67.6% [2] - The company reduced its losses by 36.3% to $28.23 million, aided by effective cost management and non-operating factors [2] - Cash and cash equivalents rose to $108 million following a global offering, significantly improving the company's financial structure with a debt-to-asset ratio reduced from 377.8% to 29.8% [2] Market Expansion - Mirxes is expanding its global market presence, with significant sales growth in China (revenue of $3.21 million, up 18.1%) and Southeast Asia (revenue of $7.26 million, with a 71.2% increase in early detection and precision multi-omics business) [3] - The company has initiated a nationwide early screening project in Japan and signed a memorandum of understanding with PT DIASTIKA BIOTEKINDO in Indonesia to advance cancer screening and molecular diagnostics [3] Product Pipeline and Competitive Advantage - Mirxes' GASTROClear, the world's first approved molecular diagnostic product for gastric cancer screening, is leading the market and has received regulatory approvals in Singapore and Thailand, as well as FDA breakthrough device designation [4] - The LUNGClear product is also performing well, contributing to revenue growth in Southeast Asia and Japan [4] - The company is advancing its R&D pipeline, with plans for the CRC-1 colorectal cancer detection product to complete prototype design in the second half of 2025 and initiate clinical trials in Singapore and China in 2026 [4] Industry Position - Mirxes holds 19 family patents and 63 pending applications, with GASTROClear included in Singapore's industry standards [5] - The company benefits from government support in Singapore, including R&D grants and tax incentives, ensuring continued innovation [6] - Mirxes was recently included in the Hang Seng Composite Index, enhancing its market influence and capital attention [6]

Core Viewpoint - The mid-term performance of Mirxes Holding Company Limited demonstrates its commercial capabilities in the field of early cancer screening [1] Financial Performance - For the first half of 2025, Mirxes achieved revenue of $10.5 million, a 9.4% increase compared to the same period in 2024, driven by a 50% growth in the early detection and precision multi-omics segment, which now accounts for 100% of the company's revenue [4] - The gross profit for this segment reached $7.1 million, reflecting a 102.9% year-on-year increase [4] - The gross margin improved from 49.0% to 67.6%, with gross profit increasing by 51.1% [5][6] - The company reported a significant reduction in losses, down 36.3% to $28.23 million, aided by effective cost management [6] Market Expansion and Strategic Partnerships - Mirxes has engaged in strategic partnerships to enhance its market presence, including a nationwide early screening project in Japan and a memorandum of understanding with PT DIASTIKA BIOTEKINDO in Indonesia [4] - The company’s flagship product, GASTROClear™, has received regulatory approval in Singapore and Thailand, and has been recognized as a "breakthrough medical device" by the FDA in the U.S. [6] Product Development and Future Outlook - The company is advancing its product pipeline, with plans for the CRC-1 colorectal cancer detection product to complete prototype design in the second half of this year and initiate clinical trials in Singapore and China in 2026 [7] - The CEO emphasized the company's commitment to accelerating the global registration process for core products and expanding its product pipeline through a multi-omics technology platform [7]

Group 1 - Grail updates its 2025 cash burn guidance to $310 million, primarily due to increased adoption of its Galleri testing product and expansion of partnerships [1] - The company reports a 93% year-over-year improvement in net loss, attributed to the growth in testing orders [1]

Core Viewpoint - The controversy surrounding Aikang Guobin has intensified, highlighting significant issues within China's private health examination market, which may lead to a pivotal change in the industry [3][4][12]. Group 1: Industry Context - The health examination market in China is projected to exceed 350 billion yuan by 2025, with Aikang Guobin and Meinian Health holding a combined market share of 60% [14]. - The industry has experienced rapid growth over the past two decades, but issues such as "wild growth" and operational challenges have become increasingly apparent [14][15]. - The need for reform in the health examination sector is underscored by the rising number of complaints against leading companies, including Aikang Guobin and Meinian Health [15]. Group 2: Examination Effectiveness - Early detection of serious diseases is challenging, and even expensive examinations may miss critical conditions [6][7]. - Many cancers, including renal clear cell carcinoma, often go undetected in early stages due to the limitations of current screening methods [7][8]. - The effectiveness of common screening methods, such as ultrasound, is limited, with a detection rate of only 60% for tumors smaller than 3 cm [8]. Group 3: Issues in the Examination Process - The health examination process is not infallible; many reports of "no abnormalities" do not guarantee the absence of disease [9]. - Overdiagnosis is a significant concern, with studies indicating that up to 99% of thyroid cancer diagnoses in individuals under 40 may be excessive [16]. - The industry faces challenges related to outdated equipment and insufficient qualified personnel, which can compromise the quality of examinations [15]. Group 4: Future Outlook - The demand for early detection of severe diseases is expected to grow, particularly with an aging population and the rise of conditions like cancer and Alzheimer's [18]. - The integration of AI technology is anticipated to enhance the health examination process, with market penetration expected to rise from 15% to 40% between 2025 and 2030 [18]. - Recent regulatory changes aim to improve the quality and reliability of health examinations, focusing on both process and outcome quality [18].